KORU Medical Systems Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2023

The following table summarizes the activities for our Plans for the nine months ended September 30, 2023, and 2022.

Schedule of time based stock options

	September 30,
	2023		2022

Dividend yield		0.00%		0.00%
Expected Volatility		54.8% - 61.3%		65.9% - 77.5%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10		10
Risk-free rate		3.50% - 4.05%		1.81% - 2.99%

The following table summarizes the status of the stock options:

	Nine Months Ended September 30,
	2023			2022
	Shares	Weighted Average Exercise Price		Shares	Weighted Average Exercise Price

Outstanding at January 1	3,035,000	$	3.93	3,672,500	$	3.42
Granted	185,000	$	3.18	770,000	$	2.68
Exercised	—	$	—	831,250	$	1.57
Forfeited	—	$	—	486,250	$	2.73
Outstanding at September 30	3,220,000	$	3.88	3,125,000	$	3.84
Options exercisable at September 30	1,333,750	$	4.57	825,000	$	4.41
Weighted average fair value of options granted during the period	—	$	2.23	—	$	2.03
Stock-based compensation expense	—	$	1,626,408	—	$	1,564,027

The following table presents information pertaining to options outstanding at September 30, 2023:

Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$2.25-$9.49	3,220,000	8.3 years	$	3.88	1,333,750	$	4.57

	Nine Months Ended September 30,
	2023			2022
	Shares	Weighted Average Grant-Date Fair Value		Shares	Weighted Average Grant-Date Fair Value

Unvested at January 1	950,000	$	3.04	—	$	—
Granted	54,496	$	3.68	1,000,000	$	3.01
Vested	100,000	$	3.31	50,000	$	3.31
Forfeited/canceled	—	$	—	—	$	—
Unvested at September 30	904,496	$	2.97	950,000	$	2.99